Regular use of paracetamol and risk of liver cancer: a prospective cohort study

BMC Cancer

Table 3 Sensitivity analysis for the association between paracetamol use and risk of liver cancer

	Case/Person-years	Hazard Ratio [95% Confidence Interval]
	Case/Person-years	Crude model	Multivariable-adjusted model^a	Propensity score-weighted model ^b
Lagging the exposure for 2 years
Non paracetamol user	411/4 297 789	1.00 [Reference]	1.00 [Reference]	1.00 [Reference]
Paracetamol user	158/1 227 698	1.46 [1.21, 1.75]	1.24 [1.02, 1.51]	1.31 [1.08, 1.59]
Stabilized inverse probability of treatment weighting analysis
Non paracetamol user	456/4 304 030	1.00 [Reference]	1.00 [Reference]	1.00 [Reference]
Paracetamol user	171/1 229 448	1.41 [1.18, 1.68]	1.22 [1.01, 1.48]	1.32 [1.08, 1.60]
After excluding viral hepatitis and cirrhosis
Non Paracetamol user	430/4 290 920	1.00 [Reference]	1.00 [Reference]	1.00 [Reference]
Paracetamol user	156/1 225 665	1.37 [1.14, 1.64]	1.20 [0.99, 1.47]	1.25 [1.03, 1.52]

^aMultivariable adjusted model: adjusted for age, sex, UK Biobank assessment centers,race, smoking, alcohol consumption, physical activity, fruit and vegetable intake, meat intake, sleep time, BMI, concomitant comorbidities (hypertension, diabetes, hyperlipidemia, viral hepatitis, cirrhosis), current medication (multivitamin, mineral supplements, aspirin, ibuprofen, PPI, histamine-2 receptor antagonists, antihypertensive drugs, antidiabetic drugs, and statin), overall health rating, Long-standing illness, and family history of cancers
^bPropensity score–weighted model using inverse probability weighting method: propensity score was derived by multivariate logistic regression conditional on aforementioned covariates, and stabilized weight was calculated for each individual

ISSN: 1471-2407